Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.
Celldex Therapeutics Inc (NASDAQ: CLDX) announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines. CSU is characterized by the occurrence of hives or weals for six weeks or longer without identifiable specific triggers or causes. Data show that multiple doses of barzolvolimab resulted in dose-dependent decreases in itch and hives, with a mean UAS7 reduction of 66.6% in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in 3.0
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg dose group (reflects one dose; ongoing)--Complete response (UAS7=0) of 57.1% in 1.5 mg/kg dose group at week 12 and 44.4% at 8 weeks in 3 mg/kg dose group (reflects one dose; ongoing)--42% of patients treated with barzolvolimab had prior omalizumab and had simila